US Archives - Page 70 of 79 - European Medical Journal

Erratum: Ozanimod Long-Term Safety and Efficacy

In the infographic published under AMJ Neurology, on 30th May 2024, the graphs depicting safety over time titled ‘Malignancy TEAEs’…

AMJ Neurology is out now!

AMJ’s inaugural neurology edition covers the latest new insights from the space – ranging from the intricacies of ageing and Alzheimer’s…

Review of the 76th American Academy of Neurology (AAN) Annual Meeting

DENVER, Colorado, USA, was the backdrop for the 2024 American Academy of Neurology (AAN) Annual Meeting. Coined as the Mile High City…

AMJ Neurology 1.1 2024

This issue features exclusive interviews with key thought leaders across various clinical areas, peer-reviewed articles, and an…

Interview: Yaakov Stern

When I was doing my BA in psychology, I found myself more interested in the research side of the subject; a lot of people who were…

AAN 2024 Abstract Highlights

AGE-related cognitive decline leads to greater entropic descriptiveness in connected speech tasks, according to new research presented at…

Updated Study Data for Ozanimod in Relapsing Multiple Sclerosis

Presenting data from ENLIGHTEN and DAYBREAK, covering cognitive processing, brain volume, disability progression, rebound, and…

Ozanimod Long-Term Safety and Efficacy

S1P receptor 1 and 5 modulator for relapsing forms of MS in adults, including clinically isolated syndrome, relapsing-remitting disease…

New Frontiers in Alzheimer’s Disease

THIS YEAR’s American Academy of Neurology (AAN) Annual Meeting, held in Denver, Colorado, USA, from April 13–18, featured an insightful…

Emerging Neuroinfectious Diseases

Delve into research regarding newly recognized pathogens, and the challenges they present to global health. Discussions explored a range…